2020-10-08 08:43Press release

CRISPR – awarded with the Nobel Prize and commercialized by TIGERQ AB

David Yudovich, CEO of TIGERQDavid Yudovich, CEO of TIGERQ

Yesterday, the discovery of one of Molecular Biology's sharpest tools, the CRISPR-Cas9 genetic scissors, was awarded the Nobel Prize in Chemistry 2020. Researchers can use these to change the DNA of animals, plants and microorganisms with extremely high precision. TIGERQ AB is commercializing services to validate the effects of this genetic tool, with extreme accuracy and precision. The company is a member of SmiLe Incubator at Medicon Village in Lund, Sweden.

The discovery of the CRISPR-Cas9 gene editing technology was presented in 2012, and since then the technology has had a revolutionary impact on the life sciences. The gene editing tool has the potential to transform how we do research, making it faster, more cost effective, and much more accurate. Already today, CRISPR research is accelerating new treatments for cancer and genetic diseases, making the dream of using gene therapy to cure inherited diseases a much closer target.

However, with the new technology there is a need to validate results, and to check the efficiency and genetic outcomes from the DNA editing process. And this is actually the TIGERQ offer: high accuracy and precision analysis services that determine the exact results of both really large and small DNA changes that develop during the CRISPR-Cas9 treatment.

“TIGERQ is fortunate to be part of this journey that is pushing the limits of research and medicine to higher levels than ever before. For us this is an incredible moment that validates our position in the market and our important role in life science research. Over the past six years the field – including biomedical, agricultural, and other technical applications – has exploded into a global market of nearly 4 billion Euro”, says David Yudovich, CEO of TIGERQ.

“We are so happy on behalf of the team at TIGERQ, that the technology the company is working with is given the most honorable prize in science. TIGERQ is a SmiLe company that has a given place in the very forefront of chemistry and life science”, says Ebba Fåhraeus, CEO of SmiLe Incubator. 


TIGERQ is founded on the basis of the research from Lund University by David Yudovich and Jonas Larsson. The company is commercializing its analytic services at the business incubator SmiLe Incubator at Medicon Village, Lund, Sweden.


For more information, please contact: David Yudovich, David.Yudovich@TIGERQ.com

Language: English

About SmiLe Venture Hub – Pioneering Life Science Innovations

SmiLe Incubator is a life science business incubator based in Medicon Village in Lund. SmiLe helps entrepreneurs to commercialize their ideas. There are currently 25 companies in SmiLe, which together with alumni companies, have attracted more than EUR 280 million in venture capital to date since 2014. SmiLe offers business coaching, a large network of contacts and a dynamic community, as well as well-equipped laboratories which is unique of its kind in Sweden. SmiLe is a non-profit organization and receives basic funding from Region Skåne, Lund Municipality, Lund University and Medicon Village. SmiLe´s sponsors are Agilent, Sparbanken Skåne, Awa, Høiberg, Prevas, Setterwalls, Zacco, Aqilion. SmiLe’s listed alumni companies have a market capitalization of almost EUR 750 million (Q4 2019). www.smileincubator.life